BillionToOne – Weekly Recap

BillionToOne is a precision diagnostics company focused on ultra-sensitive cancer and prenatal testing, and this weekly recap highlights two developments that underscore both its growing global clinical footprint and increasing executive visibility. The company announced that CEO Oguzhan Atay, PhD, has been profiled in Onyx’s CEO feature series for The Onyx Life Sciences Report, with the piece scheduled for publication in Fortune in 2026. The feature reportedly explores the origins of BillionToOne, recent milestones, and its physics-informed technology platform for solving complex biological problems, particularly in oncology and prenatal screening.

This forthcoming Fortune profile signals rising external recognition of BillionToOne’s leadership and technology. While no financial metrics were disclosed, heightened visibility in a mainstream business outlet could support brand awareness among clinicians, industry partners, and potential investors. Over time, such exposure may aid the company in capital raising, strategic collaborations, and talent recruitment, reinforcing its positioning in the competitive precision diagnostics and molecular testing markets.

On the clinical side, BillionToOne achieved a significant milestone in Japan. Its Northstar Select liquid biopsy has been chosen as the primary genomic testing platform for LC-SCRUM-TRY, a nationwide, multi-center study focused on treatment-resistant non-small cell lung cancer (NSCLC). Led by the National Cancer Center Hospital East and involving more than 100 institutions, the study has evaluated around 2,000 cases of advanced or recurrent NSCLC and is transitioning from tissue-based biopsies to plasma-based cell-free DNA testing to address limitations such as tumor accessibility and patient reluctance toward invasive procedures. Beginning November 2025, Northstar Select will serve as the preferred assay for comprehensive genomic profiling in this cohort.

Northstar Select’s selection followed comparative evaluations that emphasized the need for higher sensitivity, especially for rare or low-frequency variants. Built on BillionToOne’s single-molecule NGS platform and proprietary QCT technology, the test has demonstrated superior sensitivity in peer-reviewed head-to-head prospective data, detecting variants at allele frequencies as low as 0.15% and outperforming other commercial assays for therapy selection. The assay already meets Medicare MolDx coverage criteria in the U.S., which supports its clinical and economic validation.

Taken together, the high-profile clinical adoption in Japan and the upcoming CEO feature in Fortune point to a week of strategic progress for BillionToOne, strengthening both its scientific credibility and market visibility as it continues to scale its oncology and prenatal diagnostics offerings.